Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: An analysis of patients in Radiation Therapy Oncology Group Protocol 86-10

Clinical Cancer Research

Volumn 10, Issue 12 I, 2004, Pages 4118-4124

  Li, Rile ^a   Heydon, Kateri ^b   Hammond, M Elizabeth ^c   Grignon, David J ^d   Roach III, Mack ^e   Wolkov, Harvey B ^f   Sandler, Howard M ^g   Shipley, William U ^h   Pollack, Alan ⁱ  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b AMERICAN COLLEGE OF RADIOLOGY   (United States)

^c Latter Day Saints Hospital   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Sutter Medical Center   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67;

ADVANCED CANCER; AGED; ARTICLE; BEAM THERAPY; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; STAINING; STAINING INDEX;

AGED; CELL PROLIFERATION; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ODDS RATIO; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 3042663353     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1052-03     Document Type: Article

References (20)

1. Scott R, Hall P, Haldane J, et al. A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Clin Pathol 1991;165:173-8.
2. van Weerdan W, Moerings E, van Kreuningen A, et al. Ki-67 expression and BrdUrd incorporation as markers of proliferative activity in human prostate tumour models. Cell Prolif 1993;26:67-75.
3. Cher M, Chew K, Rosenau W, Carroll P. Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate 1995;26:87-93.
4. Wilson G, Saunders M, Dische S, et al. Direct comparison of bromodeoxyuridine and Ki-67 labeling indices in human tumours. Cell Prolif 1996;29:141-52.
5. Bubendorf L, Sauter G, Moch H, et al. Ki-67 labeling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996;178:437-41.
6. Bettencourt M-C, Bauer J, Sesterhenn I, et al. Ki-67 expression is a prognotic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996;156:1064-8.
7. Stapleton A, Zbell P, Kattan MW, et al. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer (Phila) 1998;82:168-75.
8. Stattin P, Damber J-E, Karlberg L, Bergh A. Cell proliferation assessed by Ki-67 immunoreactivity of formalin fixed tissues is a predictive factor for survival in prostate cancer. J Urol 1997;157:219-22.
9. Halvorsen OJ, Haukaas S, Hoisaeter PA, Akslen LA. Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy. Anticancer Res 2001;21:4071-6.
10. Scalzo D, Kallakury B, Gaddipati R, et al. Cell proliferation rate by MIB-1 immunohistochemistry predicts postradiation recurrence in prostatic adenocarcinomas. Am J Clin Pathol 1998;109:163-8.
11. Khoo V, Pollack A, Cowen D, et al. Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate 1999;41:166-72.
12. Cowen D, Troncoso P, Khoo VS, et al. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin Cancer Res 2002;8:1148-54.
13. Pilepich MV, Winter K, John MJ, et al. Phase III Radiation Therapy Oncology Group (RTOG) Trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52.
14. Grignon DJ, Caplan R, Sarkar FH, et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst (Bethesda) 1997;89:158-65.
15. Pollack A, Grignon DJ, Heydon KH, et al. Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610. J Clin Oncol 2003;21:1238-48.
16. Pilepich MV, Krall JM, Al-Sarraf M, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45:616-23.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:447-57.
18. Kalbfleisch JD, Ross LP. The statistical analysis of failure time data. New York: John Wiley & Sons; 1980.
19. Harris E, Albert A. Survivorship analysis for clinical studies. New York: Marcel Dekker; 1991. p. 5-125.
20. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.